Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Deciphering the Interplay of Depleting Anti-PD-1 Antibodies and Autoimmune Environments in Type-1 Diabetes: Towards Better Utility of Therapeutic Antibody

Award Number: R01AI187812
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/19/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2031

Group Awards By:

View Award Description

Deciphering the Interplay of Depleting Anti-PD-1 Antibodies and Autoimmune Environments in Type-1 Diabetes: Towards Better Utility of Therapeutic Antibody - PROJECT SUMMARY This project aims to investigate the interactions and impacts between a depleting antibody (D-aPD-1) that targets programmed death-1-expressing (PD-1+) cells and the autoimmune environment in type 1 diabetes (T1D). PD- 1+ cells are primarily effector lymphocytes that are diabetogenic in T1D.These PD-1+ cells could be a potential target for suppressing autoimmunity in T1D. Initial studies demonstrated that eliminating PD-1+ cells with a PD- 1-specific immunotoxin delayed hyperglycemia onset in NOD mice with late insulitis (L-insulitis). However, immunotoxins are not ideal for chronic disease management, leading to the development of D-aPD-1 as an alternative. Interestingly, when administered to mice with early insulitis (E-insulitis), D-aPD-1 delayed hyperglycemia onset, suggesting a protective effect. However, when given to L-insulitis mice, it unexpectedly accelerated hyperglycemia onset, indicating a pro-autoimmune response. Furthermore, unlike D-aPD-1, PD-1 immunotoxin delayed hyperglycemia onset in L-insulitis mice. These findings align with clinical observations that disease stages and therapeutic agens influences treatment outcomes, highlighting the need to elucidate the mechanisms driving these contrasting responses for better desing and application of T1D therapeutics. To address these questions, this project will investigate the hypothesis that both the immune milieu of T1D and the characteristics of PD-1+ cell-depleting agents play key roles in determining treatment outcomes. Aim 1 will uncover the immune determinants of D-aPD-1’s divergent treatment outcomes in E and L-insulitis by profiling pancreatic islets and systemic immune cells before and after D-aPD-1 treatment. We will use single-cell RNA sequencing (scRNA-seq) and flow cytometry to dentify changes in immune cell populations and pathways associated with pro- and -anti-autoimmune effects. Additionally, strategies to shift L-insulitis responses toward an E-insulitis-like profile will be explored through modulate certain immune cell types. Aim 2 will define the mechanism underlying differential responses to D-aPD-1 and PD-1 immunotoxin by comparing immune cell dynamics and gene expression changes following the treatments. We will identify key cellular mediators responsible for the pro-autoimmune response induced by D-aPD-1, while also investigating whether depleting these responsive cell populations can mitigate its adverse effects. Aim 3 will establish that Fc-free PD-1+ cell depleting agents protect L-insulitis mice from hyperglycemia. Specifically, we will assess whether the Fc-free PD-1+ depleting agents, including albumin-amended antibody-drug conjugate (A3DC) and bispecific killer cell engager (BiKE), can eliminate PD-1+ cells without triggering pro-autoimmune effects. This research could advance targeted PD-1+ cell depletion strategies, leading to safer and more effective antibody-based treatments for T1D. By addressing immune context and therapeutic design, the findings may tailor the design and application of therapeutics for T1D patients at different stages.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $756,078 )
2026	2026	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	1	2/19/2026	NEW	$756,078
														Subtotal = $756,078

Grand Total All Awards = $756,078

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Deciphering the Interplay of Depleting Anti-PD-1 Antibodies and Autoimmune Environments in Type-1 Diabetes: Towards Better Utility of Therapeutic Antibody

Award Number: R01AI187812

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/19/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer